Zymeworks downgraded by Wells Fargo with a new price target
$ZYME
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo downgraded Zymeworks from Overweight to Equal Weight and set a new price target of $12.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/20/2025 | Buy | TD Cowen | |
| 12/16/2024 | $18.00 | Neutral → Overweight | Analyst |
| 11/7/2024 | $10.00 → $25.00 | Market Perform → Outperform | Leerink Partners |
| 11/1/2024 | $12.00 | Overweight → Equal Weight | Wells Fargo |
| 3/21/2023 | $12.00 | Overweight | Wells Fargo |
| 1/4/2023 | $10.00 → $8.00 | Neutral | H.C. Wainwright |
| 12/20/2022 | $7.70 → $11.00 | Hold → Buy | Jefferies |
| 11/1/2022 | $40.00 → $8.00 | Buy → Neutral | H.C. Wainwright |
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
4 - Zymeworks Inc. (0001937653) (Issuer)
TD Cowen initiated coverage of Zymeworks with a rating of Buy
Analyst upgraded Zymeworks from Neutral to Overweight and set a new price target of $18.00
Leerink Partners upgraded Zymeworks from Market Perform to Outperform and set a new price target of $25.00 from $10.00 previously